Breakthrough in CAR-T Therapy Achieved by Chinese Sun Yat-sen University Cancer Center

Recently, Professor Huang Huiqiang’s team at Sun Yat-sen University Affiliated Cancer Hospital achieved significant progress in a lymphoma patient who relapsed after five lines of chemotherapy. Utilizing CAR-T therapy, the patient has experienced complete remission for over two years, making them one of the patients in China with the longest survival post-CAR-T treatment.

Lymphoma, one of the common blood cancers, has traditionally been treated using a combination of chemotherapy, autologous hematopoietic stem cell transplantation, targeted therapies, and immune-modulating drugs. However, CAR-T cell therapy, an advanced technology in the field of oncology, has emerged as a precise, rapid, and highly effective new treatment method in recent years.

Diffuse large B-cell lymphoma is a prevalent aggressive lymphoma characterized by rapid progression, high mortality rates, and short survival periods. Despite significant therapeutic advancements in recent years, approximately 70% of patients achieve good outcomes and long-term remission through first-line treatments, but around 30% of patients have inadequate responses to treatment, facing difficult-to-cure relapses.

Professor Huang Huiqiang emphasized, “CAR-T cell therapy plays a crucial role in providing new treatment hopes for relapsed and refractory patients who cannot undergo transplantation or have previously undergone ineffective treatments.

It is reported that in the future, Sun Yat-sen University Cancer Center will continue to explore clinical innovative technologies in CAR-T cell therapy, aiming to bring new prospects for numerous patients.

#CARTBreakthrough #CancerResearch #SunYatSenCancerCenter #InnovativeTherapies #MedicalBreakthrough #LymphomaTreatment #PrecisionMedicine #HopeForPatients #CancerSurvivorship #AdvancedOncology #MedicalInnovation #ResearchProgress #ScienceNews #HealthcareAdvancements #ImmunotherapySuccess #Cancer